De novo device clearances fall out of fashion
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Gilead-Galapagos deal rescues a slow licensing year
Up-front fees paid out by biopharma companies to seal licensing deals noticeably dipped in the second quarter of the year – then Gilead and Galapagos came along.
Few medtechs go public, but those that do, do nicely
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
Venture investing dips again for biopharma
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
Medtech VC and the billion-dollar era
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
Biopharma set for a big buyout year – on dollar terms at least
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
Big device deals are back in fashion
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.